In the treatment of NSCLC with EGFR-TKIs, the presence of a rash has been shown to significantly predict the effectiveness of the treatment, particularly in patients with unknown EGFR mutation status [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.